Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

JPM24: Caris crafts collabs with AbbVie, Flatiron to bring AI-powered genomic database to drug development That includes ...

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

While at Merck, George led the merger integration of Merck and Schering ... Our life sciences customers’ ability to navigate the complex, emerging data fueling the next generation of drug discovery ...

However, that is less true for large-cap stocks like Merck and Bristol-Myers. Still, it’s important to understand why ...

New research points to taking melatonin 3 hours before bedtime but some experts say it is still best to take the supplement ...

The collaboration with Merck KGaA, Darmstadt, Germany focuses on discovering ... stage biopharmaceutical company focused on ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...